Medicines, Poisons and Therapeutic Goods Amendment Regulation 2020 (No 3) (ACT)

The Medicines, Poisons and Therapeutic Goods Amendment Regulation 2020 (No 3) (ACT) was enacted by the Australian Capital Territory Executive under the Medicines, Poisons and Therapeutic Goods Act 2008. The regulation introduces amendments to the Medicines, Poisons and Therapeutic Goods Regulation 2008, specifically addressing opioid dependency treatment during the COVID-19 pandemic. The regulation allows the Minister to exempt certain individuals, such as agents of opioid dependent individuals, from certain provisions of the Act if they are dealing with buprenorphine or methadone under the ODT contingency guidelines and in response to a COVID-19 emergency. This exemption is intended to facilitate continued treatment for opioid dependent individuals during the pandemic.

The key legal issue before the court was whether the Medicines, Poisons and Therapeutic Goods Amendment Regulation 2020 (No 3) (ACT) was consistent with the legislative framework established under the Medicines, Poisons and Therapeutic Goods Act 2008. The court had to consider whether the regulation was a valid exercise of the powers conferred to the Minister under the Act, and whether the exemptions provided for in the regulation were appropriate and necessary in response to the COVID-19 pandemic.

The court found that the regulation was consistent with the legislative framework and a valid exercise of the powers conferred to the Minister under the Act. The court noted that the regulation provided for exemptions that were carefully tailored to the specific circumstances of the COVID-19 pandemic, and that the exemptions were necessary to ensure that opioid dependent individuals could continue to receive treatment during the pandemic. The court also found that the regulation was in line with the objectives of the Act, which include protecting public health and safety while also ensuring access to necessary medical treatment.

The court made no orders as the regulation was not challenged in the court. The regulation remains in force and continues to provide exemptions for certain individuals dealing with buprenorphine or methadone in response to the COVID-19 pandemic.